Rivaroxaban, a factor Xa inhibitor, induces the secondary prevention of cardiovascular events after myocardial ischemia reperfusion injury in mice-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Rivaroxaban, a factor Xa inhibitor, induces the secondary prevention of cardiovascular events after myocardial ischemia reperfusion injury in mice

Published:2016-10 Issue: Volume:220 Page:602-607
ISSN:0167-5273
Container-title:International Journal of Cardiology
language:en
Short-container-title:International Journal of Cardiology

Author:

Goto Masaki,Miura Shin-ichiro,Suematsu Yasunori,Idemoto Yoshiaki,Takata Kouhei,Imaizumi Satoshi,Uehara Yoshinari,Saku Keijiro

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference33 articles.

1. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation;Patel;N. Engl. J. Med.,2011

2. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation;Hori;Circ. J.,2012

3. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation;Granger;N. Engl. J. Med.,2011

4. The ENGAGE AF-TIMI 48 investigators. Edoxaban versus warfarin in patients with atrial fibrillation;Giugliano;N. Engl. J. Med.,2013

5. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature;Dentali;Circulation,2012

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rivaroxaban for patients with coronary dissection after drug-coated balloon angioplasty : A Randomized Controlled Trial;2024-01-07

2. Rivaroxaban attenuates neutrophil maturation in the bone marrow niche;Basic Research in Cardiology;2023-08-14

3. Emerging roles of protease-activated receptors in cardiometabolic disorders;Journal of Cardiology;2023-04

4. The effect of rivaroxaban on biomarkers in blood and plasma: a review of preclinical and clinical evidence;Journal of Thrombosis and Thrombolysis;2023-02-06

5. Interaction of Cardiovascular Nonmodifiable Risk Factors, Comorbidities and Comedications With Ischemia/Reperfusion Injury and Cardioprotection by Pharmacological Treatments and Ischemic Conditioning;Pharmacological Reviews;2022-12-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3